Enhancement of the inhibitory effect of an IL-15 antagonist peptide by alanine scanning

Journal of Peptide Science

Volumn 18, Issue 1, 2012, Pages 25-29

  Savio, Alicia Santos ^a   Acosta, Osvaldo Reyes ^a   Pérez, Haydee Gerónimo ^a   Álvarez, Yunier Rodríguez ^a   Chico, Araceli ^b   Pérez, Hilda Garay ^a   Ojeda, Miriam Ojeda ^a   Aguero, Celia Aurora Arrieta ^a   Estévez, Miguel ^b   Nieto, Gerardo Guillen ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

Author keywords

Antagonist; Cytokine; IL 15; Peptide; Receptor alpha

Indexed keywords

ALANINE; CYSTEINE; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 15; INTERLEUKIN 15 ANTAGONIST PEPTIDE P8; INTERLEUKIN 15 RECEPTOR ALPHA; LYSINE; PHENYLALANINE; THREONINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL PROLIFERATION; CYTOKINE RELEASE; DRUG ANTAGONISM; DRUG SYNTHESIS; GENE MUTATION; HUMAN; IC 50; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE;

ALANINE; AMINO ACID SEQUENCE; ARTHRITIS, RHEUMATOID; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; LYSINE; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SYNOVIAL FLUID; T-LYMPHOCYTES; THREONINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84355162078     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1411     Document Type: Article

References (22)

1. Waldmann TA. IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends Mol. Med. 2003; 9(12): 517-521.
2. Giri JG, Kumaki S, Ahdieh DJ, Loomis A, Shanebeck K, DuBose R, Cosman D, Park LS and Anderson DM. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 1995; 14: 3654-3663.
3. Bulanova E, Budagian V, Duitman E, Orinska Z, Krause H, Ruckert R, Reiling N, Bulfone-Paus S. Soluble IL-15Rα is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J. Biol. Chem. 2007; 282(18): 13167-79.
4. Budagian V, Bulanova E, Orinska Z, Pohl T, Borden EC, Silverman R, Bulfone-Paus S. Reverse signalling through membrane bound interleukin-15. J. Biol. Chem. 2004; 279: 42192-42201.
5. Rubinstein M, Kovar M, Purton J, Cho J, Boyman O, Surh C, Sprent J. Converting IL-15 to a superagonist by binding to soluble IL-15Rα. PNAS. 2006; 103: 9166-9171.
6. McInnes IB, Al-Mughales J, Field M, Leung BP, Huang F-P, Dixon R, Sturrock RD, Wilkinson PC, Liew FY. The role of interleukin 15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 1996; 2: 175.
7. Liu Z, Geboes K, Colpaert S, D'Haens GR, Rutgeerts P, Ceuppens JL. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J. Immunol. 2000; 164: 3608-3615.
8. Agostini C, Trentin L, Facco M, Sancetta R, Cerutti A, Tassinari C, Cimarosto L, Adami F, Cipriani A, Zambello R, Semenzato G. Role of IL-15, IL-2 and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J. Immunol. 1996; 157(2): 910-8.
9. Kivisakk P, Matusevicius D, He B, Soderstrom M, Fredrikson S, and Link H. IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS). Clin. Exp. Immunol. 1998; 111: 193-197.
10. Baslund B, Tvede N, Danneskiold-Samsoe B, Petersen J, Petersen LJ, Schuurman J, de Winkel JV, Larsson P, Panayi G, McInnes LB. A novel human monoclonal antibody against IL-15 (humax-IL15) in patients with active rheumatoid arthritis (RA): results of a double-blind, placebo-controlled phase I/II trial. Arthritis Rheum. 2003, 48(suppl. 9): S1706.
11. Kim YS, Maslinski W, Zheng XX, Stevens AC, Li XC, Tesch GH, Kelley VR, Strom TB. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcγ2a protein blocks delayed-type hypersensitivity. J. Immunol. 1998; 160: 5742-5748.
12. Ruchatz HB, Leung P, Wei XQ, McInnes IB and Liew FY. Soluble IL-15 receptor a-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J. Immunol. 1998; 160: 5654-5660.
13. Santos A, Cabrales A, Reyes O, Gerónimo H, Rodríguez Y, Garay H, Arrieta C, Silva R, Guillen G. Identification of an interleukin-15 antagonist peptide that binds to IL-15Rα. Biotecnología Aplicada 2008; 25(4): 320-324.
14. Kukar M, Petryna O, Efthimiou P. Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics: Targets & Therapy 2009; 3: 443-457.
15. Bernard J, Harb C, Mortier E, Quemener A, Meloen RH, Vermot-Desroches C, Wijdeness J, van Dijken P, Grotzinger J, Slootstral JW, Plet A, Jacques Y. Identification of an interleukin-15α receptor-binding site on human interleukin-15. J. Biol. Chem. 2004; 279: 24313-24322.
16. Chirifu M, Hayashi C, Nakamura T, Toma S, Shuto T, Kai H, Yamagata Y, Davis SJ, Ikemizu S. Crystal structure of the IL-15-IL-15Ralpha complex, a cytokine-receptor unit presented in trans. Nat. Immunol. 2007; 8(9): 1001-7.
17. Olsen SK, Ota N, Kishishita S, Kukimoto-Niino M, Murayama K, Uchiyama H, Toyama M, Terada T, Shirouzu M, Kanagawa O, Yokoyama S. Crystal structure of the interleukin-15. Interleukin-15 receptor α complex. J. Biol. Chem. 2007; 282: 37191-37204.
18. Thurkow EW, van der Heijden IM, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, Meinders AE, Tak PP: Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J. Pathol. 1997; 181: 444-450.
19. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat. Med. 1997; 3: 189-195.
20. Sebbag M, Parry SL, Brennan FM, Feldmann M. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur. J. Immunol. 1997; 27(3): 624-32.
21. Field GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Peptide Protein Res. 1990; 35(3): 161-214.
22. Andreu D, Albericio F, Sole NA, Munson NC, Ferrer M, Barany G. Peptide Synthesis Protocols. Humana Press Inc.: Totowa, New Jersey, 1994; 91-116.